A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

This study is testing a new antibody-drug combination (SHR-A1811) as a treatment given before surgery for women with early-stage or locally advanced HER2-positive breast cancer. HER2-positive means the cancer has a protein that makes it grow faster. The goal is to see how well this treatment shrinks the tumor before surgery. **You may be eligible if...** - You are a woman aged 18–75 receiving treatment for the first time - Your breast cancer is confirmed HER2-positive by a pathology test - You are in generally good health (ECOG score 0–1) - You agree to use contraception and have a negative pregnancy test **You may NOT be eligible if...** - Your cancer is HER2-negative - You have already received cancer treatment - You are allergic to the study drug - You are currently enrolled in another clinical trial - You have received a vaccine within 30 days before starting treatment Talk to your doctor to see if this trial is right for you.